Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era

doi:10.3748/wjg.v29.i13.2015

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 13

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3197)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-7) series.

Item

Count

PDF

155

WORD

HTML

1761

Figures (1-3)

316

Tables (1-7)

253

Sum=2535

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

166

Download

496

Sum=662

Apr 7, 2023 (publication date) through Aug 25, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Apr 7, 2023; 29(13): 2015-2033
Published online Apr 7, 2023. doi: 10.3748/wjg.v29.i13.2015

Table 3 Treatment characteristics in six-time intervals

Parameter	2015-2016	2017	2018	2019	2020	2021
Number of patients	1199	827	573	438	199	341
History of previous therapy
Treatment-naïve	543 (45.3)	532 (64.3)	470 (82.0)	385 (87.9)	171 (86)	318 (93.2)
Nonresponder	290 (24.2)	103 (12.5)	23 (4.0)	7 (1.6)	6 (3)	11 (3.2)
Relapser	173 (14.4)	72 (8.7)	49 (8.5)	35 (8)	17 (8.5)	6 (1.8)
Discontinuation due to safety reason	71 (5.9)	40 (4.8)	14 (2.5)	4 (0.9)	1 (0.5)	3 (0.9)
Unknown type of response	120 (10.0)	76 (9.2)	14 (2.5)	7 (1.6)	2 (1)	3 (0.9)
No data	2 (0.2)	4 (0.5)	3 (0.5)	0	2 (1)	0
Number of patients with treatment failure	n = 654	n = 291	n = 100	n = 53	n = 26	n = 23
IFN ± RBV	64 (9.8)	36 (12.4)	2 (2)	0	0	0
PegIFN ± RBV	390 (59.6)	197 (67.7)	48 (48)	14 (26.4)	9 (34.6)	9 (39.1)
PegIFN + RBV + DAA	196 (30)	47 (16.1)	10 (10)	3 (5.7)	0	0
IFN-free	4 (0.6)	11 (3.8)	39 (39)	35 (66)	17 (65.4)	14 (60.9)
No data	0	0	1 (1)	1 (1.9)	0	0
Current treatment regimen
Genotype-specific treatment regimens
ASV + DCV	42 (3.5)	13 (1.6)	0	0	0	0
LDV/(SOF ± RBV)	350 (29.2)	283 (34.2)	154 (26.9)	16 (3.7)	5 (2.5)	4 (1.2)
OBV/PTV/(r ± DSV ± RBV)	745 (62.1)	327 (39.5)	32 (5.6)	0	0	1 (0.3)
GZR/(EBR ± RBV)	0	97 (11.7)	205 (35.8)	76 (17.3)	16 (8)	15 (4.4)
Other	62 (5.2)	104 (12.6)	19 (3.3)	0	0	0
SOF ± SMV ± DCV ± RBV, SMV ± DCV ± RBV
Pangenotypic regimens
GLE/PIB	0	1 (0.1)	59 (10.3)	178 (40.6)	99 (49.8)	117 (34.3)
GLE/(PIB + SOF + RBV)	0	0	0	2 (0.5)	0	0
SOF/(VEL ± RBV)	0	2 (0.3)	104 (18.1)	166 (37.9)	79 (39.7)	195 (57.2)
VOX/VEL/SOF	0	0	0	0	0	9 (2.6)
Current-RBV-containing therapies	855 (71.3)	360 (43.5)	163 (28.4)	44 (10)	12 (6)	23 (6.7)

IFN: Interferon; RBV: Ribavirin; PegIFN: Pegylated interferon; DAA: Direct-acting antivirals; ASV: Asunaprevir; DCV: Daclatasvir; LDV: Ledipasvir; SOF: Sofosbuvir; OBV: Ombitasvir; PTV/r: Paritaprevir; DSV: Dasabuvir; GZR: Grazoprevir; EBR: Elbasvir; SMV: Simeprevir; GLE: Glecaprevir; PIB: Pibrentasvir; VEL: Velpatasvir; VOX: Voxilaprevir.

Citation: Brzdęk M, Zarębska-Michaluk D, Rzymski P, Lorenc B, Kazek A, Tudrujek-Zdunek M, Janocha-Litwin J, Mazur W, Dybowska D, Berak H, Parfieniuk-Kowerda A, Klapaczyński J, Sitko M, Sobala-Szczygieł B, Piekarska A, Flisiak R. Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era. World J Gastroenterol 2023; 29(13): 2015-2033
URL: https://www.wjgnet.com/1007-9327/full/v29/i13/2015.htm
DOI: https://dx.doi.org/10.3748/wjg.v29.i13.2015